Skip to main navigation

Home
Tech
Purpose
- Mission
- The Promise
- Faster
- Global
About
- Team
- Company
- Investors
- Careers
- Contact
Menu Menu

Publications.

Investor Menu

Investor Relations

Overview
News
Press Releases Publications
Investor Presentation & Events
Presentations Events
Governance
Directors Leadership Scientific Advisory Board Manufacturing and Quality Advisory Board Committee Composition Documents & Charters
Stock Information
Stock Quote & Chart Analyst Coverage Ownership Profile
Financials & Filings
SEC Filings Annual Reports and Proxies Quarterly Results
Investor Resources
Investor FAQs Email Alerts Contact IR

August 23, 2024

Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study

Source: MDPI

July 20, 2022

SARS-CoV-2 oral tablet vaccination induces neutralizing mucosal IgA in a phase 1 open label trial

Source: medRxiv

May 19, 2022

Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model

Source: Science Translation Medicine

February 24, 2022

Mucosal Immunization of Cynomolgus Macaques with Adenoviral Vector Vaccine Elicits Neutralizing Nasal and Serum Antibody to Several SARS-CoV-2 Variants

Source: bioRxiv

October 7, 2021

Oral and intranasal Ad5 SARS-CoV-2 vaccines decrease disease and viral transmission in a golden hamster model

Source: bio-Rxiv

November 9, 2020

Source: USA Today

September 8, 2020

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

Source: bioRxiv

January 21, 2020

Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study

Source: The Lancet

Welcome
Tech
Mission
Investors

Terms of Use
Privacy Policy

© Copyright - Vaxart 2024

LinkedIn
Twitter
Youtube